View Exam | PowerPak

1. In the NIH COVID-19 Treatment Guidelines, which of the following patient categories is listed in “Tier 1” or highest priority for COVID-19 outpatient antiviral treatment.

A. Unvaccinated persons aged 75 and over B. Persons aged 75 and over regardless of vaccination status C. Persons aged 65 and over regardless of vaccination status D. Any unvaccinated individual E. Unsure

2. Medication categories identified by the CDC as causing a reduced immune response to COVID-19 vaccines include:

A. HMG-CoA reductase inhibitors B. SGLT2 inhibitors C. anti-CD20 monoclonal antibodies D. all of the above E. Unsure

3. The optimal window of time to start an outpatient COVID-19 antiviral regimen would be:

A. if COVID-19 symptoms have not abated by 1 week B. while the person awaits results from a polymerase chain reaction (PCR) test for COVID-19 C. after exposure and before a person develops COVID-19 symptoms D. within 5 days of developing COVID-19 symptoms E. Unsure

4. Which of the following accurately describes the components of the oral antiviral agent Paxlovid?

A. nirmatrelvir monotherapy B. nirmatrelvir plus remdesivir booster C. nirmatrelvir plus ritonavir booster D. ritonavir plus nirmatrelvir booster E. Unsure

5. The recommended oral dose of molnupiravir for a 38-year-old, 63-kg woman with COVID-19 is

A. 800 mg once daily for 5 days B. 800 mg twice daily for 5 days C. 800 mg on day 1 followed by 400 mg once daily for 5 days D. 400 mg twice daily for 5 days E. Unsure

6. The correct remdesivir dosing recommendations for a 50-year-old nonhospitalized male with COVID-19 is:

A. 200 mg IV loading dose on day 1, 200 mg IV dose on days 2 and 3 B. 200 mg IV loading dose on day 1, 100 mg IV dose on days 2 and 3 C. single IV infusion of 200 mg D. 200 mg IV once daily for 5 days E. Unsure

7. The monoclonal antibody bebtelovimab for COVID-19 treatment is:

A. no longer recommended due to inactivity against Omicron BA.2 B. used only in hospitalized patients with COVID-19 who are not on ventilators C. approved for outpatient use as a series of 3 IV daily doses D. approved for outpatient use as a single IV dose E. Unsure

8. Nirmatrelvir plus ritonavir (Paxlovid) is associated with drug-drug interactions because:

A. nirmatrelvir potentiates CYP3A, and thereby decreases the effectiveness of drugs cleared by CYP3A B. ritonavir inhibits CYP3A and thereby may cause toxicity in drugs cleared by CYP3A C. ritonavir should not be given with drugs that induce CYP3A because their plasma concentrations would be lowered D. both ritonavir and nirmatrelvir interact with drugs metabolized by CYP3A E. Unsure

9. A 69-year-old patient tests positive for COVID-19 and is symptomatic. He is taking amiodarone for the treatment of an arrhythmia, is at high risk for severe COVID-19 disease, and has not received a COVID-19 vaccine. He lives in a rural area a long distance from medical services. Which treatment approach is best for this patient?

A. nirmatrelvir and ritonavir (Paxlovid) B. remdesivir C. molnupiravir or bebtelovimab D. no antiviral medications E. Unsure

10. The most recent FDA authorization for pharmacists to prescribe Paxlovid contains certain restrictions, including:

A. pharmacists should verify medication list and liver/kidney labs within the previous 12 months B. pharmacists must call the patient's physician to authorize the prescription C. pharmacists must first retest the patient for COVID-19 using a polymerase chain reaction (PCR) test D. pharmacists can prescribe if they are part of a collaborative practice agreement overseen by a physician or nurse practitioner E. Unsure

Evaluation Questions

11. How confident are in your treatment choices for the 69-year-old patient in the question above?

A. Not at all confident B. Somewhat confident C. Confident D. Highly confident

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. In the NIH COVID-19 Treatment Guidelines, which of the following patient categories is listed in “Tier 1” or highest priority for COVID-19 outpatient antiviral treatment.

2. Medication categories identified by the CDC as causing a reduced immune response to COVID-19 vaccines include:

3. The optimal window of time to start an outpatient COVID-19 antiviral regimen would be:

4. Which of the following accurately describes the components of the oral antiviral agent Paxlovid?

5. The recommended oral dose of molnupiravir for a 38-year-old, 63-kg woman with COVID-19 is

6. The correct remdesivir dosing recommendations for a 50-year-old nonhospitalized male with COVID-19 is:

7. The monoclonal antibody bebtelovimab for COVID-19 treatment is:

8. Nirmatrelvir plus ritonavir (Paxlovid) is associated with drug-drug interactions because:

10. The most recent FDA authorization for pharmacists to prescribe Paxlovid contains certain restrictions, including:

Evaluation Questions

11. How confident are in your treatment choices for the 69-year-old patient in the question above?

« Return to Activity

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

The shopping cart is empty

Customers who Purchasedthis Activity also Purchased

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. In the NIH COVID-19 Treatment Guidelines, which of the following patient categories is listed in “Tier 1” or highest priority for COVID-19 outpatient antiviral treatment.

2. Medication categories identified by the CDC as causing a reduced immune response to COVID-19 vaccines include:

3. The optimal window of time to start an outpatient COVID-19 antiviral regimen would be:

4. Which of the following accurately describes the components of the oral antiviral agent Paxlovid?

5. The recommended oral dose of molnupiravir for a 38-year-old, 63-kg woman with COVID-19 is

6. The correct remdesivir dosing recommendations for a 50-year-old nonhospitalized male with COVID-19 is:

7. The monoclonal antibody bebtelovimab for COVID-19 treatment is:

8. Nirmatrelvir plus ritonavir (Paxlovid) is associated with drug-drug interactions because:

10. The most recent FDA authorization for pharmacists to prescribe Paxlovid contains certain restrictions, including:

Evaluation Questions

11. How confident are in your treatment choices for the 69-year-old patient in the question above?

« Return to Activity

Customers who Purchased
this Activity also Purchased